{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:27:09Z","timestamp":1792553229968,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cancer therapy-related cardiac dysfunction (CTRCD) is a critical problem with an impact on both oncological and cardiovascular prognosis, especially when it prevents patients from receiving cancer treatment. Standard therapy for heart failure (HF) is recommended for CTRCD, but there is no well-established evidence on how sacubitril\/valsartan may help cancer patients with cardiotoxicity.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The aim of this trial was to study the effectiveness of sacubitril-valsartan in patients with CTRCD treated in cardio-oncology units.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We enrolled 635 patients with breast cancer and followed them with echocardiography and NT- proBNP. Patients who developed left ventricular dysfunction and heart failure were treated with angiotensin-converting enzyme inhibitors (ACEI) (enalapril) or angiotensin receptor blockers (ARB) (valsartan), aldosterone antagonists (eplerenone), digitalis and diuretics (furosemide), as needed. When patients remained symptomatic and met the PARADIGM-HF inclusion criteria, sacubitril\/valsartan was started instead of enalapril or valsartan.<\/jats:p>\n                <jats:p>We analyzed clinical, laboratory and echocardiographic variables to determine the beneficial effects of sacubitril\/valsartan on left ventricular remodeling (improvement of left ventricular ejection fraction (LVEF), left ventricle internal diameter in diastole), diastolic dysfunction (E\/e\u2019 ratio), reduction in NT-proBNP levels, New York Heart Association (NHYA) class and improvement in the 6-min walk test.<\/jats:p>\n                <jats:p>Also, we analyzed serum creatinine and potassium levels to determine treatmentsafety in this population. Median follow-up was 20\u2009months.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-eight patients developed cardiotoxicity and were treated with sacubitril\/valsartan. The sacubitril\/valsartan dose was 100\u2009mg (sacubitril 49\u2009mg\/valsartan 51\u2009mg) in 12 patients (42.85%) and 200\u2009mg (sacubitril 97\u2009mg\/valsartan 103\u2009mg) in 16 patients (57.15%). No deaths were reported, and one patient underwent heart transplantation.<\/jats:p>\n                <jats:p>Baseline median NT-proBNP was 997.5\u2009pg\/ml (IQR 663.8 \u2014 2380.8), which decreased to a median of 416.5\u2009pg\/ml (IQR 192.0\u2013798.2) on follow-up with <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001.<\/jats:p>\n                <jats:p>Baseline NYHA functional class was III (78.6%) or IV (21.4%), and it improved to I (57.1%) or II (42.9%) on follow-up. LVEF increased with treatment from 26.7\u2009\u00b1\u20095.4% to 32.3\u2009\u00b1\u20095.5% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). There were also significant improvements in left ventricle internal diameter in diastole (LVIDD), diastolic function, 6-min walk test, and mitral valve regurgitation. There were no differences between basal and follow-up levels of serum creatinine or potassium.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Sacubitril\/valsartan might be a promising treatment option in patients with refractory CTRCD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40959-020-00078-4","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T06:02:52Z","timestamp":1604556172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Use of Sacubitril\/valsartan in patients with cardio toxicity and heart failure due to chemotherapy"],"prefix":"10.1186","volume":"6","author":[{"given":"Vanesa","family":"Gregorietti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Lopez","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u00edas Ortega","family":"Chahla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J.","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"issue":"8","key":"78_CR1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18(8):891\u2013975.","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"78_CR2","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"J Zamorano","year":"2016","unstructured":"Zamorano J, Lancellotti P, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: \u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768\u2013801.","journal-title":"Eur Heart J"},{"key":"78_CR3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"MJ Mac","year":"2014","unstructured":"Mac MJ, Packer M, et al. Angiotensin- Neprilysin inhibition versus Enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"issue":"9","key":"78_CR4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","volume":"89","author":"J Herrmann","year":"2014","unstructured":"Herrmann J, Lerman A, et al. Evaluation and Mangement of patients with heart failure and Cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287\u2013306.","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"78_CR5","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014 Sep;27(9):911\u201339.","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"78_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jamacardio.2018.0398","volume":"3","author":"A Chandra","year":"2018","unstructured":"Chandra A, et al. Effects of Sacubitril\/valsartan on Phisycal and social activity limitations in patients with heart failure. A secundary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2018;3(6):498\u2013506.","journal-title":"JAMA Cardiol"},{"key":"78_CR7","unstructured":"Porcile R et al. Remodelaci\u00f3n inversa del miocardio y reducci\u00f3n de marcadores inflamatorios en pacientes con insuficiencia card\u00edaca tratada con sacubitrilo\/valsart\u00e1n Insuficiencia Card\u00edaca, vol. 13, n\u00fam. 3, 2018."},{"issue":"11","key":"78_CR8","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","volume":"139","author":"DH Kang","year":"2019","unstructured":"Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, et al. Angiotensin receptor Neprilysin inhibitor for functional mitral regurgitation. Circulation. 2019;139(11):1354\u201365.","journal-title":"Circulation"},{"key":"78_CR9","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1161\/CIRCULATIONAHA.118.038135","volume":"139","author":"W Mullens","year":"2019","unstructured":"Mullens W, Martens P. Sacubitril\/valsartan to reduce secondary mitral regurgitation. Refinement of GuidelineDirected medical therapy? Circulation. 2019;139:1366\u201370.","journal-title":"Circulation"},{"issue":"5","key":"78_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1177\/1078155218783238","volume":"25","author":"E Christina","year":"2019","unstructured":"Christina E. Sheppard, Maria Anwar. The use of sacubitril\/valsartan in Anthracycline-induced cardiomyopathy: a mini case series. J Oncol Pharm Pract. 2019;25(5):1231\u20134.","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"78_CR11","first-page":"1097","volume":"73","author":"K Morris","year":"2019","unstructured":"Morris K, et al. Novel use of valsartan-sacubitril as treatment for trastuzumab induced cardiomyopathy. J Am Coll Cardiol. 2019;73(9) Supplement 1:1097.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"78_CR12","first-page":"316","volume":"2","author":"M Camilli","year":"2020","unstructured":"Camilli M, Del Buono M, Crea F, Minotti G. Acute heart failure 29 years after treatment for childhood Cancer. JACC. 2020;2(2):316\u20139.","journal-title":"JACC"},{"issue":"Suppl. S1","key":"78_CR13","first-page":"562","volume":"20","author":"V Gregorietti","year":"2018","unstructured":"Gregorietti V, et al. Use of sacubitril valsartan in heart failure due to postchemotherapy symptomatic ventricular dysfunction. Eur J Heart Fail. 2018;20(Suppl. S1):562.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"78_CR14","first-page":"1","volume":"7","author":"A Mart\u00edn-Garcia","year":"2020","unstructured":"Mart\u00edn-Garcia A, L\u00f3pez-Fern\u00e1ndez T, et al. Effectiveness of sacubitril\u2013valsartan in cancer patients with heart failure. ESC Heart Fail. 2020;7(2):1\u20135.","journal-title":"ESC Heart Fail"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-020-00078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40959-020-00078-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-020-00078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T18:04:03Z","timestamp":1604599443000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-020-00078-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["78"],"URL":"https:\/\/doi.org\/10.1186\/s40959-020-00078-4","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]},"assertion":[{"value":"4 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}